ZA200300085B - 7-hydroxyepiandrosterone having neuroprotective activity. - Google Patents

7-hydroxyepiandrosterone having neuroprotective activity. Download PDF

Info

Publication number
ZA200300085B
ZA200300085B ZA200300085A ZA200300085A ZA200300085B ZA 200300085 B ZA200300085 B ZA 200300085B ZA 200300085 A ZA200300085 A ZA 200300085A ZA 200300085 A ZA200300085 A ZA 200300085A ZA 200300085 B ZA200300085 B ZA 200300085B
Authority
ZA
South Africa
Prior art keywords
hydroxyepiandrosterone
epia
substance
composition
hydroxy
Prior art date
Application number
ZA200300085A
Other languages
English (en)
Inventor
Ashley Ker Pringle
Ernst Wuelfert
Lars Eric Sundstrom
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of ZA200300085B publication Critical patent/ZA200300085B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200300085A 2000-06-29 2003-01-03 7-hydroxyepiandrosterone having neuroprotective activity. ZA200300085B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone

Publications (1)

Publication Number Publication Date
ZA200300085B true ZA200300085B (en) 2004-04-21

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300085A ZA200300085B (en) 2000-06-29 2003-01-03 7-hydroxyepiandrosterone having neuroprotective activity.

Country Status (24)

Country Link
US (2) US7718639B2 (zh)
EP (1) EP1294382B1 (zh)
JP (1) JP4942905B2 (zh)
KR (1) KR100786284B1 (zh)
CN (1) CN100459980C (zh)
AT (1) ATE401897T1 (zh)
AU (2) AU2001267709B2 (zh)
CA (1) CA2414584C (zh)
CY (1) CY1108773T1 (zh)
CZ (1) CZ299676B6 (zh)
DE (1) DE60134979D1 (zh)
DK (1) DK1294382T3 (zh)
ES (1) ES2310182T3 (zh)
GB (1) GB2363983A (zh)
HK (1) HK1052300B (zh)
HU (1) HU227152B1 (zh)
IL (2) IL153541A0 (zh)
NO (1) NO327959B1 (zh)
PL (1) PL200699B1 (zh)
PT (1) PT1294382E (zh)
RU (1) RU2307654C2 (zh)
SI (1) SI1294382T1 (zh)
WO (1) WO2002000225A1 (zh)
ZA (1) ZA200300085B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
EP1539183A4 (en) * 2002-08-28 2007-04-25 Hollis Eden Pharmaceuticals THERAPEUTIC TREATMENT METHODS
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
HUE026961T2 (en) 2006-11-21 2016-07-28 Umecrine Cognition Ab Use of pregnant and androstane steroids for the manufacture of a medicament for the treatment of central nervous system disorders
MX2009005753A (es) 2006-11-30 2009-09-28 Hunter Fleming Ltd Modulacion de trayectorias metabolicas de prostaglandina/ciclooxig enasa.
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5532230A (en) 1993-03-09 1996-07-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5976850A (en) 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GEP20012530B (en) 1995-06-06 2001-09-25 Cocensys Inc Neuroactive Steroids of the Androstane and Pregnane Series
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
NZ331975A (en) * 1996-04-09 2000-12-22 Btg Int Ltd Use of 7 alpha-substituted steroids to treat neuropsychriatic disorders or enhance cognition
EP0929574B1 (en) 1996-08-27 2005-06-29 Praecis Pharmaceuticals Incorporated MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
WO1999015179A1 (en) * 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999024400A1 (en) 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
EP1032397A1 (en) * 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitors and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
ATE361309T1 (de) 1999-11-02 2007-05-15 Bayer Schering Pharma Ag 18-nor-steroide als selektiv wirksame estrogene
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
IL153541A0 (en) 2003-07-06
CN1440290A (zh) 2003-09-03
NO327959B1 (no) 2009-10-26
CY1108773T1 (el) 2014-04-09
ATE401897T1 (de) 2008-08-15
IL153541A (en) 2008-03-20
HU227152B1 (en) 2010-08-30
RU2307654C2 (ru) 2007-10-10
AU2001267709B2 (en) 2005-07-28
HUP0301134A2 (hu) 2003-08-28
EP1294382A1 (en) 2003-03-26
KR20030034113A (ko) 2003-05-01
RU2003102437A (ru) 2005-01-27
NO20026243D0 (no) 2002-12-27
HK1052300B (zh) 2009-01-30
HK1052300A1 (en) 2003-09-11
JP2004501196A (ja) 2004-01-15
ES2310182T3 (es) 2009-01-01
CA2414584A1 (en) 2002-01-03
SI1294382T1 (sl) 2009-02-28
DK1294382T3 (da) 2008-11-24
DE60134979D1 (de) 2008-09-04
GB2363983A (en) 2002-01-16
US20030166626A1 (en) 2003-09-04
CA2414584C (en) 2009-10-27
CZ299676B6 (cs) 2008-10-15
KR100786284B1 (ko) 2007-12-18
US7718639B2 (en) 2010-05-18
HUP0301134A3 (en) 2006-06-28
PL200699B1 (pl) 2009-01-30
NO20026243L (no) 2003-02-27
CZ200377A3 (cs) 2003-06-18
AU6770901A (en) 2002-01-08
PL359108A1 (en) 2004-08-23
GB0016022D0 (en) 2000-08-23
US20100173883A1 (en) 2010-07-08
JP4942905B2 (ja) 2012-05-30
CN100459980C (zh) 2009-02-11
PT1294382E (pt) 2008-10-21
EP1294382B1 (en) 2008-07-23
WO2002000225A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
US20100173883A1 (en) 7-hydroxyepiandrosterone having neuroprotective activity
US20100130459A1 (en) Neuroprotective 7-beta-hydroxysteroids
AU2001267705A1 (en) Neuroprotective 7-beta-hydroxysteroids
AU2001267709A1 (en) 7-hydroxyepiandrosterone having neuroprotective activity
CA1065851A (fr) Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procede
JP4541698B2 (ja) ヒドロキシステロイドの予防的および治療的使用
WO2024007684A1 (zh) 一种新型Nrf2激活剂及用途
JP2001506628A (ja) 抗酸化剤としてのエキレニンの使用
EP1996291B1 (en) Use of digitalis-like compounds in the treatment of affective disorders
WO2007123234A1 (ja) 抗てんかん作用増強剤
JP2001506629A (ja) 医療用抗酸化剤として使用するための17α−ジヒドロエキレニン
BE818863A (fr) Therapie au moyen de derives de la progesterone